Stock Market Update - October 29, 2025
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. CMBM - Cambium Networks Corporation
Price: $2.95 | Change: +377.35% ($2.332)
CMBM absolutely rocketed, gaining a massive 377.35%! This dramatic surge came after Cambium Networks announced a game-changing partnership with Starlink around October 30, 2025.
The big news was that Cambium's "ONE Network" solution will integrate with Starlink's satellite internet to provide enterprise-grade service. This means businesses using Starlink will get much better management, reliability, and optimized performance through Cambium's tools. Think features like combining multiple Starlink connections for faster speeds, automatic backup if one connection fails, and easy monitoring of their Starlink dishes through Cambium's cloud system.
What makes this especially noteworthy is how Cambium is stepping in to fill a crucial gap. While Starlink has been popular, it's been missing robust tools for big businesses. This collaboration positions Cambium to secure significant new contracts and potentially see a big boost in ongoing revenue, which clearly excited investors.
2. PPBT - Purple Biotech Ltd.
Price: $1.06 | Change: +81.82% ($0.477)
PPBT:NASDAQ saw its shares surge an impressive 81.82%. This dramatic rise came after Purple Biotech announced a major manufacturing breakthrough for its experimental cancer drug, IM1240. On October 29, 2025, the clinical-stage biopharmaceutical company revealed it had achieved a commercially viable yield and high-purity process for IM1240, a complex antibody designed to fight tumor immune evasion and drug resistance.
This manufacturing milestone is a big deal because it validates the scalability of their CAPTN-3 platform for developing sophisticated treatments. It's a crucial step that positions IM1240 competitively for future development and human trials, with Purple Biotech planning to submit an Investigational New Drug (IND) application in 2026. Investors showed strong confidence in this progress, sending the stock soaring.
3. PUMP - ProPetro Holding Corp.
Price: $11.1 | Change: +52.05% ($3.8)
PUMP:NYSE soared 52.05% around late October, following two significant developments for ProPetro Holding Corp.
The initial surge came after its subsidiary, PROPWR, secured a landmark long-term contract. This deal will supply 60 megawatts of power to a leading data center operator using an innovative hybrid energy system. This agreement is seen as a major milestone, establishing a strategic relationship and positioning PROPWR ahead of competitors in the evolving power supply market.
Further fueling the rise, ProPetro then reported better-than-expected third-quarter financial results, with revenues of $294 million surpassing analyst estimates. This strong performance, combined with the PROPWR contract, significantly boosted investor confidence in ProPetro's aggressive electrification strategy, highlighting its potential for future growth and expanded margins.
4. ERNA - Ernexa Therapeutics Inc.
Price: $1.76 | Change: +40.80% ($0.51)
ERNA surged 40.80% following a major announcement from Ernexa Therapeutics Inc. The biotech company revealed a strategic manufacturing collaboration with Cellipont Bioservices, a crucial step for advancing their lead cancer cell therapy, ERNA-101.
This partnership aims to develop and scale up the production of ERNA-101, which is designed as an "off-the-shelf" treatment, meaning it could be readily available for patients. Preclinical studies have shown this innovative therapy's potential to reprogram tough-to-treat "cold" tumors, making them more receptive to the body's immune response.
This collaboration is a significant milestone for Ernexa, helping to translate the promising lab results of their cell therapy platform into a potential clinical treatment for advanced solid tumors. The news generated considerable optimism, driving the notable jump in its stock price.
5. MCTA - Charming Medical Limited Class A Ordinary Shares
Price: $19.14 | Change: +34.69% ($4.93)
MCTA just saw a significant 34.69% gain, grabbing investor attention. This notable rise for Charming Medical Limited, a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies, is largely attributed to its recent successful Initial Public Offering (IPO) on the Nasdaq Capital Market on October 21, 2025. Shares were initially priced at $4.00 each.
A key driver of the recent upward movement was the full exercise of the underwriters' over-allotment option. This means strong investor demand prompted the underwriters to purchase an additional 240,000 shares, bringing in an extra $0.96 million and boosting total gross proceeds to around $7.36 million. This signals robust confidence in the newly public company.
Charming Medical plans to use these proceeds to fuel its business expansion, explore strategic investments, fund research and development, and for general working capital. The positive market sentiment following its Nasdaq debut, combined with clear plans for growth, has made MCTA a stock capturing market interest.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.